Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Michael Gale · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $1,164,339 — CORE D PROJECT SUMMARY The `Omics, Bioinformatics, and Data Management Core (Core D) serves this Program by providing high resolution functional genomics and bioinformatics computation analyses with statistical integration. The main objective of the Core is to define the gene expression signatures a…
Chinthalapally V. Rao · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2024 · $764,880 — Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 receptors. Patients with TNBC have a significantly lower 5-year survival rate compared to other breast cancer types. Mol…
BRUXANNE EL-KAMMASH · UNIVERSITY OF CHICAGO · 2024 · $3,691,826 — Vaccines are formulated with adjuvants to stimulate the immune system so that the vaccine can be more effective at preventing disease. Our goal is to create an adjuvant formulation that overcomes a limitation in many adjuvants - customization of the immune response for a desired immunological outco…
Courtney Cohen · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $3,193,054 — In vivo efficacy testing is essential for the down-selection, evaluation, and development of potent and effective medical countermeasures (MCMs), especially given that many aspects of viral replication and pathogenesis cannot be faithfully recapitulated in vitro. Core D is responsible for providing …
Barton F. Haynes · DUKE UNIVERSITY · 2024 · $3,846,023 — While HIV-1 broadly neutralizing antibodies (bnAbs) provide potent protection from HIV-1, to date they have been difficult to induce in the setting of vaccination. A second type of HIV-1 envelope (Env) antibodies that are easy to induce are termed non-neutralizing antibodies (NNAbs) (because they ar…
Charles Bix Shoemaker · TUFTS UNIVERSITY BOSTON · 2024 · $206,250 — Schistosomes are parasitic flatworms that cause a chronic, debilitating disease afflicting >200 million people in >70 countries. Since there are limited anti-schistosome drugs available and since these is no vaccine to prevent infection, we aim here to generate and test nanobody-based immunotherapeu…
Ajay Bansal · UNIVERSITY OF KANSAS MEDICAL CENTER · 2024 · $172,197 — ABSTRACT The central goal of this R50 Clinician Scientist Award application is to establish and refine processes that facilitate clinical trials in cancer interception at The University of Kansas Cancer Center (KUCC), a unique goal that is different from the majority of R50 applicants which focus on…
HONGMIN LI · UNIVERSITY OF ARIZONA · 2024 · $767,382 — Abstract: Flaviviruses are primarily insect-borne, associated with global morbidity and mortality, and found on every inhabited continent. Unfortunately, current therapeutic options for treating diseases associated with these viruses are limited. All flaviviruses encode methyltransferases (MTases)—f…
Rachel Adria Katzenellenbogen · INDIANA UNIVERSITY INDIANAPOLIS · 2024 · $357,616 — PROJECT SUMMARY/ABSTRACT High-risk human papillomaviruses (HR HPVs) cause 5% of all cancers. There are preventive vaccines against HPV, but less than 2% of the world's target population has received them. This leaves millions of women and men at risk for HPV-associated cervical, anogenital, and hea…
TINEKE CANTAERT · INSTITUT PASTEUR DU CAMBODGE · 2024 · $583,119 — We currently have a very limited understanding of the factors, either genetic or immune-related, conferring protection to clinical Plasmodium vivax (Pv) malaria. Deciphering the mechanisms underlying such protection would allow the design of tailored intervention strategies for the elimination of Pv…
Daniel F. Hoft · SAINT LOUIS UNIVERSITY · 2024 · $667,594 — -γ-producing Th1 cells have been extensively studied for development of novel vaccines and therapeutics against Mycobacterium tuberculosis (Mtb) infection. However, recent studies demonstrate that Mtb-specific Th1 cells alone do not predict protection against tuberculosis (TB). Therefore, although T…
Roger Sciammas · UNIVERSITY OF CALIFORNIA-IRVINE · 2024 · $773,817 — Project summary: The vast majority of mammalian genes produce alternatively processed mRNAs through alternative splicing and alternative polyadenylation (APA). Different mRNA isoforms produced from the same gene can encode distinct proteins and/or they may be differentially regulated. Recent studies…
GILLIAN L BEAMER · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2024 · $532,829 — PROJECT SUMMARY/ABSTRACT Throughout modern history, tuberculosis (TB) has killed more people than any other infectious disease to date (estimated > 2 billion people over the past 350 years) and TB continues to kill 4,000 patients each day. In 2019 alone, the World Health Organization estimated that …
Laurent Karl Verkoczy · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $953,504 — PROJECT SUMMARY Developing a preventative HIV vaccine remains a global health priority and to be effective will most likely need to elicit broadly neutralizing antibodies (bnAbs). HIV bnAbs are derived from rare, unmutated common ancestor (UCA) B-cell precursors in elite HIV+ human repertoires. To …
ROBIN J SHATTOCK · IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE · 2024 · $344,112 — Abstract/summary There is currently no vaccine in clinical use to combat group A streptococcal infection, despite the considerable global burden of acute and chronic disease attributable to this pathogen. The long-term goal of this work is the development of a combination vaccine that can combat gro…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $1,582,499 — ABSTRACT OVERALL The main goal of our IPCAVD Program grant is to evaluate in humans self-amplifying mRNA (saRNA) vaccines that express two HIV-1 Env-derived protein immunogens that activate and initiate the maturation of VRC01-class B cell receptors (BCRs). The first immunogen, 426c.Mod.Core, was sp…
Dipak Kumar Raj · UNIVERSITY OF SOUTH FLORIDA · 2024 · $375,000 — Project Summary The overall aim of this application is to advance PfCDPK5 and PfGARP as vaccine candidates for falciparum malaria. P.falciparum malaria affects almost one-half of the world's population and causes more than 500,000 deaths annually. Young children in malaria endemic areas of Africa h…
Genoveffa Franchini · DIVISION OF BASIC SCIENCES - NCI · 2024 · $249,755 — HTLV-1A is the most common form of HTLV-1 worldwide and causes leukemia and inflammatory diseases such as the neurodegenerative HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). HTLV-1C, first genetically characterized in Melanesia in the early 1990s, is endemic in indigenous Aust…
Patrick Duffy · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $2,649,684 — From our publications this year, we report the following advances in FY2024: 1. Duffy PE, Gorres JP, Healy SA, Fried M. Malaria Vaccines: A New Era. 2024. Nature Reviews Microbiology. Jul 18. doi: 10.1038/s41579-024-01065-7. In this major review article, we provided an overview of the malaria probl…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2024 · $2,399,995 — Project Summary The goal of this Center of Biomedical Research Excellence is to continue our efforts to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approa…